MedTrace Logo

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

NCT01134705 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 474

Last updated 2012-05-23

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of perennial allergic rhinitis.

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol

Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol

DRUG

Placebo Nasal Aerosol

HFA Vehicle Aerosol

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Sudeesh Tantry, Ph.D. · Teva Branded Pharmaceutical Products R&D, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01134705 on ClinicalTrials.gov